Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov-Dec;18(6):925-929.
doi: 10.4103/1008-682X.181192.

The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study

Yi-Shuo Wu  1   2 , Ning Zhang  1   2 , Sheng-Hua Liu  1   2 , Jian-Feng Xu  1   2   3 , Shi-Jun Tong  1   2 , Ye-Hua Cai  4 , Li-Min Zhang  1   2 , Pei-De Bai  1   2 , Meng-Bo Hu  1   2 , Hao-Wen Jiang  1   2 , Rong Na  1   2 , Qiang Ding  1   2 , Ying-Hao Sun  5
Affiliations

The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study

Yi-Shuo Wu et al. Asian J Androl. 2016 Nov-Dec.

Abstract

The performances of the Prostate Cancer Prevention Trial (PCPT) risk calculator and other risk calculators for prostate cancer (PCa) prediction in Chinese populations were poorly understood. We performed this study to build risk calculators (Huashan risk calculators) based on Chinese population and validated the performance of prostate-specific antigen (PSA), PCPT risk calculator, and Huashan risk calculators in a validation cohort. We built Huashan risk calculators based on data from 1059 men who underwent initial prostate biopsy from January 2006 to December 2010 in a training cohort. Then, we validated the performance of PSA, PCPT risk calculator, and Huashan risk calculators in an observational validation study from January 2011 to December 2014. All necessary clinical information were collected before the biopsy. The results showed that Huashan risk calculators 1 and 2 outperformed the PCPT risk calculator for predicting PCa in both entire training cohort and stratified population (with PSA from 2.0 ng ml-1 to 20.0 ng m). In the validation study, Huashan risk calculator 1 still outperformed the PCPT risk calculator in the entire validation cohort (0.849 vs 0.779 in area under the receiver operating characteristic curve [AUC] and stratified population. A considerable reduction of unnecessary biopsies (approximately 30%) was also observed when the Huashan risk calculators were used. Thus, we believe that the Huashan risk calculators (especially Huashan risk calculator 1) may have added value for predicting PCa in Chinese population. However, these results still needed further evaluation in larger populations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of the study population and study design.
Figure 2
Figure 2
The ROC curves of PSA, PCPT risk calculator, RC 1, and RC 2 in predicting PCa in the training cohort. ROC: receiver operating characteristic; PCa: prostate cancer.
Figure 3
Figure 3
The ROC curves of PSA, PCPT risk calculator, RC 1, and RC 2 in predicting PCa in the validation cohort. ROC: receiver operating characteristic; PCa: prostate cancer.
See this image and copyright information in PMC

Comment in

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Liu M, Wang JY, Zhang YG, Zhu SC, Lu ZH, et al. [Detection of urological and male genital tumors diagnosed in Beijing hospital 1995-2004] Zhonghua Yi Xue Za Zhi. 2007;87:2423–5. [Article in Chinese] - PubMed
    1. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046–55. - PMC - PubMed
    1. Gann PH, Ma J, Catalona WJ, Stampfer MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol. 2002;167:2427–34. - PubMed
    1. Cavadas V, Osorio L, Sabell F, Teves F, Branco F, et al. Prostate Cancer Prevention Trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. Eur Urol. 2010;58:551–8. - PubMed

Publication types

Substances